title: Soybean phenolic-rich extracts inhibit key-enzymes linked to type 2 diabetes (α-amylase and α-glucosidase) and hypertension (angiotensin I converting enzyme) in vitro.
abstract: This study sought to assess the inhibitory activities of phenolic-rich extracts from soybean on α-amylase, α-glucosidase and angiotensin I converting enzyme (ACE) activities in vitro. The free phenolic extract of the soybean was obtained by extraction with 80% acetone, while that of the bound phenolic extract was done by extracting the alkaline and acid hydrolyzed residue with ethyl acetate. The inhibitory action of these extracts on the enzymes activity as well as their antioxidant properties was assessed. Both phenolic-rich extracts inhibited α-amylase, α-glucosidase and ACE enzyme activities in a dose dependent pattern. However, the bound phenolic extract exhibited significantly (P < 0.05) higher α-amylase and ACE inhibition while the free phenolic extract had significantly (P < 0.05) higher α-glucosidase inhibitory activity. Nevertheless, the free phenolic extract had higher α-glucosidase inhibitory activity when compared to that of α-amylase; this property confer an advantage on soybean phenolic-rich extracts over commercial antidiabetic drugs with little or no side effect. And inhibition of ACE suggests the antihypertension potential of soybean phenolic-rich extracts. Furthermore, the enzyme inhibitory activities of the phenolic-rich extracts were not associated with their phenolic content. Therefore, phenolic-rich extracts of soybean could inhibit key-enzyme linked to type 2 diabetes (α-amylase and α-glucosidase) and hypertension (ACE) and thus could explain in part the mechanism by which soybean renders these health promoting effect.
authors: Department of Biochemistry, Federal University of Technology, Akure, P.M.B. 704, Akure 340001, Nigeria.
authors: Adedayo O
authors: AO
authors: Ademiluyi
authors: Ganiyu
authors: G
authors: Oboh
mesh_terms: D000806:Angiotensin-Converting Enzyme Inhibitors / Q000302:isolation & purification / Q000494:pharmacology; D000975:Antioxidants / Q000302:isolation & purification / Q000494:pharmacology; D003924:Diabetes Mellitus, Type 2 / Q000201:enzymology*; D004305:Dose-Response Relationship, Drug; D004791:Enzyme Inhibitors / Q000302:isolation & purification / Q000494:pharmacology*; D065089:Glycoside Hydrolase Inhibitors; D006973:Hypertension / Q000201:enzymology*; D007703:Peptidyl-Dipeptidase A / Q000378:metabolism*; D010636:Phenols / Q000302:isolation & purification*; D010936:Plant Extracts / Q000302:isolation & purification / Q000494:pharmacology; D013025:Glycine max / Q000737:chemistry*; D000516:alpha-Amylases / Q000037:antagonists & inhibitors*
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D000975:Antioxidants; D004791:Enzyme Inhibitors; D065089:Glycoside Hydrolase Inhibitors; D010636:Phenols; D010936:Plant Extracts; D000516:alpha-Amylases; D007703:Peptidyl-Dipeptidase A